Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before
ACCESSWIRE - Thu Jun 26, 8:37AM CDT
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body's immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it's one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE: MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (NASDAQ: CELG), GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVS) and more to develop antibodies to support the human immune system against cancer.
Aethlon Medical Announces Online Access to Infectious Disease and Cancer Therapy Presentation
PR Newswire - Wed Jun 25, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.
Aethlon Medical to Present at The Wall Street Analyst Forum
PR Newswire - Tue Jun 17, 11:53AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25th Annual Institutional Investor Conference on Thursday, June 19th, at 12:05 PM EDT. Mr. Joyce's presentation will include an update on a forthcoming FDA-cleared study of the Aethlon Hemopurifier®, a review of the Company's cancer programs, and a progress report on Exosome Sciences, Inc., a diagnostic subsidiary recently launched by the Company.
The Role of Aethlon Medical in the Emerging Immuno-Oncology Market; Q&A with Aethlon Chairman and CEO, Jim Joyce
PR Newswire - Tue Jun 10, 7:00AM CDT
Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB: AEMD). Mr. Joyce shares insight into the emerging Immuno-Oncology market and the opportunity it represents.
Aethlon Medical® Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients
PR Newswire - Wed May 21, 8:30AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced high rapid virologic response (RVR) and sustained virologic response (SVR) rates in Hepatitis-C virus (HCV) infected individuals who were administered Hemopurifier® therapy.
Aethlon Medical® Announces Definitive Agreement with DaVita Clinical Research and Site Location and Principal Investigator of Hepatitis C Virus (HCV) Clinical Study
PR Newswire - Tue May 20, 7:15AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into a definitive agreement with DaVita Clinical Research (DCR) to provide clinical management services to support the forthcoming feasibility study of the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon further announced that the Principal Investigator for this study will be Dr. Stephen Z. Fadem.
Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - Thu May 15, 1:18PM CDT
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen.
Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets
ACCESSWIRE - Wed May 14, 2:50PM CDT
Whitefish, MT / May 14, 2014 / Pharmaceutical companies big and small are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are receiving the praise of analysts as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465. Shares of Celldex Therapeutics (NASDAQ: CLDX) are chugging ahead by 25 percent on Wednesday after striking a deal with Bristol-Myers Squibb (NYSE: BMY) to collaborate on the clinical development of BMY's PD-1 investigational drug nivolumab in combination with Celldex's CD27-targeting drug candidate varlilumab.
Aethlon Medical (AEMD) CEO Note: Cancer Treatment Discovery, Exosomes Transport Pharmaceutical Industry Targets
PR Newswire - Wed May 14, 7:31AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target
PR Newswire - Wed Mar 19, 8:29AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases
ACCESSWIRE - Thu Mar 13, 12:21PM CDT
Whitefish MT / March 13, 2014 / The quest to address long-term neurodegenerative problems associated with traumatic brain injury (TBI) and concussions has received plenty of attention recently, in part because of high profile athletes raising awareness and also because of some breakthrough research by Boston University and the University of California at Los Angeles. With any advancement come arguments on both sides of the debate about the accuracy of statements without extensive clinical research, and the sobering reality is that there still are no reliable treatments for diseases like Alzheimer's disease and chronic traumatic encephalopathy (CTE). All scientific posturing and argumentative rhetoric aside, the fact that companies are making strides in diagnostics and more resources are being devoted to these areas of tremendous unmet medical need are reason for optimism as there are new paths being carved in the evolution of new treatments.
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders
ACCESSWIRE - Wed Mar 05, 12:30PM CST
Whitefish, MT / March 5, 2014 / Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death. There is reason for optimism, though, with hundreds of organizations working on new treatments and diagnostics, including Neuralstem (NYSE MKT: CUR), Thermo Fisher Scientific (NYSE: TMO) and Aethlon Medical (OTCBB: AEMD).
Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries
PR Newswire - Wed Mar 05, 7:29AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.
Aethlon Medical partners with DaVita Clinical Research to support the feasibility & pivotal study of Aethlon Hemopurifier
M2 - Thu Feb 27, 4:21AM CST
Therapeutic filtration company Aethlon Medical (OTC BB:AEMD) said on Wednesday that it has entered into a non-exclusive agreement to provide clinical management services to support the forthcoming studies of the Aethlon Hemopurifier.
Aethlon Medical Expands Clinical Network Through DaVita Agreement
ACCESSWIRE - Wed Feb 26, 2:01PM CST
Aethlon Medical, Inc. (OTC: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, recently signed an agreement with DaVita Clinical Research (DCR) to support upcoming studies of its Aethlon Hemopurifier®. With experience conducting more than 300 early phase clinical trials through a network of more than 150 investigative physicians, DCR is uniquely positioned to help Aethlon Medical advance its unique Hemopurifier technology. DCR's numerous locations could enable Aethlon's trials to advance more quickly than they would if they were conducted in one clinical site.
Aethlon Medical® Announces Agreement with DaVita Clinical Research®
PR Newswire - Wed Feb 26, 7:03AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.
comScore to Appoint Serge Matta Chief Executive Officer
PR Newswire - Tue Feb 11, 6:00AM CST
comScore, Inc. (NASDAQ: SCOR) today announced that its Board of Directors has appointed Serge Matta as Chief Executive Officer, effective March 1, 2014. Concurrently, Dr. Magid Abraham, comScore's co-founder and current Chief Executive Officer, will become Executive Chairman of the Board of Directors. Gian Fulgoni, comScore's co-founder and current Executive Chairman of the Board of Directors, will become Chairman Emeritus, remaining on the Company's Board of Directors and maintaining his current external-facing industry role on behalf of comScore.
New Sonatype Software Protects The World's Enterprise Software Applications From Security, Compliance, And Licensing Threats
PR Newswire - Wed Jan 29, 1:37PM CST
Sonatype, the software company that enables developers to rapidly build secure software while also eliminating compliance and licensing risk, today released a new version of its Component Lifecycle Management (CLM) software.
Travelocity's Long Weekend Sale Encourages Travelers To Escape The Winter Blues
PR Newswire - Wed Jan 29, 6:19AM CST
It's only January but residents from Dallas to New York City have already been hit with heavy snow, blizzard conditions and freezing temperatures. To combat the winter blues, Travelocity has launched its "Go and Love the Long Weekend" sale, encouraging travelers to make the most of the upcoming Presidents Day holiday with deals on wonderful warm weather getaways.
Alleghany Corporation To Announce Fourth Quarter and Fiscal Year 2013 Results On February 25, 2014
PR Newswire - Fri Jan 24, 11:31AM CST
Alleghany Corporation (NYSE-Y) will release its financial results for the fourth quarter and 2013 fiscal year after the market closes on Tuesday, February 25, 2014. In conjunction with the release, Alleghany will post its financial supplement to the company's web-site at www.alleghany.com.